Skip to content

Correlation between urinary dysfunction and abnormal brain function

Correlation between urinary dysfunction and abnormal brain function

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092006
Enrollment
Unknown
Registered
2024-11-07
Start date
2024-11-13
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory lower urinary tract dysfunction

Interventions

Patient group:None
Control group:None

Sponsors

Wuxi No. 2 People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Enrollment Criteria: A: Diagnostic criteria for interstitial cystitis: (satisfy both of the following conditions) 1) Pain in the bladder area or frequent urination and urgency; 2) Intravesical instillation of normal saline to expand the bladder (pressure reaches 80cmH2O and maintained for 3 minutes), observing more than three quadrants with 10 or more bleeding points as positive. B: Diagnostic criteria for prostatitis: 1) Those who meet the diagnostic criteria for chronic prostatitis according to Western medicine; 2) Disease duration exceeds 3 months; 3) No oral treatment with other medications within 2 weeks before entering the study cycle. C: Diagnostic criteria for bladder cancer: 1) Pathological diagnosis is the gold standard. D: Diagnostic criteria for prostate cancer: 1) Pathological diagnosis is the gold standard. E: Diagnostic criteria for overactive bladder (OAB): 1) Urgency score in the OABSS questionnaire is 2 points or above, and the total score is 3 points or above, excluding other pathological causes. Control Group Enrollment Criteria: Healthy examination personnel with age, gender, and education level matched to the refractory lower urinary tract dysfunction patients were selected from our hospital's health examination center using frequency matching. Among them, those with a HAMA scale score > 7 were included in the anxiety control group.

Exclusion criteria

Exclusion criteria: Exclusion criteria: Patients with urethral stenosis, urinary tract stones, urinary tract infection, urinary tract tumors or neurogenic bladder; women who are breastfeeding or pregnant; patients with severe heart, liver, kidney, brain and hematopoietic system diseases, central nervous system infection, head injury, epilepsy, multiple sclerosis, toxic metabolic diseases, Parkinson's disease or intracranial tumors; patients who have undergone pelvic surgery for pelvic organ prolapse or urinary incontinence; patients with a family history of genetic diseases, a history of schizophrenia or personality changes, a history of alcohol/drug dependence; patients who have taken related cognitive-improving drugs; patients with severe heart, liver, kidney, brain and hematopoietic system diseases, gynecological diseases such as vaginitis; patients with contraindications to MRI scanning (such as implanted electronic or metal devices).

Design outcomes

Primary

MeasureTime frame
Multimodal magnetic resonance imaging;

Secondary

MeasureTime frame
Hematological indicators;Hamilton Anxiety Scale;

Countries

China

Contacts

Public ContactFeng Ninghan

Wuxi No. 2 People's Hospital

n.feng@njmu.edu.cn+86 138 6189 2528

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026